Daily SPAC Update – September 4, 2024

DECA + Semnur Pharmaceuticals Deal. MITA and SKGR Extension Votes Set. IFIN DeSPAC. APXI Removes MultiplAI from Deal. GLLI PIPE. DYCQ LOI Announced.

 Boardroom Alpha SPAC Resources
– Full SPAC Listing
– SPAC SEC Filings
– Boardroom Alpha IPO & SPAC Intelligence Platform (7-Day Trial)

Daily SPAC Update

SPAC DEAL & EXTENSION VOTES SET
MITA – Coliseum Acquisition Corp * EXTENSION VOTE SET: Sep 20, 2024 * trust $11.13
SKGR – Sk Growth Opportunities Corp * EXTENSION VOTE SET: Sep 26, 2024 * trust $11.28

SPAC DEALS ANNOUNCED
Sep 03 | DECA – Denali Capital Acquisition Corp + Semnur Pharmaceuticals, Inc.

DeSPACs
IFIN -> CURR on Sep 03

OTHER SPAC NEWS
APXI – APX ACQUISITION CORP I * Deal modification: MultiplAI removed from deal
GLLI – GLOBALINK INVESTMENT INC * Deal PIPE adjustments
DYCQ – DT CLOUD ACQUISITION CORP * Non-Binding LOI

SPAC LIQUIDATIONS
TortoiseEcofin Acquisition Corp. III (TRTLF)-> Liquidation on Sep 06
Fintech Ecosystem Development Corp. (FEXD)-> Liquidation on Aug 29

YESTERDAY’S TOP SPAC GAINERS
13.17% ~ $ 12.20 | ACAC – Acri Capital Acquisition Corp (Announced)
2.81% ~ $ 10.61 | PTWO – Pono Capital Two, Inc. (Announced)
2.23% ~ $ 11.00 | IRAA – Tribe Capital Growth Corp I (Announced)
2.04% ~ $ 12.50 | ADRT – Ault Disruptive Technologies Corp (Pre-Deal)

YESTERDAY’S TOP SPAC LOSERS
-5.86% ~ $ 11.65 | ALSA – Alpha Star Acquisition Corp (Pre-Deal)
-3.35% ~ $ 11.68 | CLOE – Clover Leaf Capital Corp. (Announced)
-.86% ~ $ 11.50 | TRON – Corner Growth Acquisition Corp. 2 (Pre-Deal)
-.84% ~ $ 10.57 | BHAC – Focus Impact BH3 Acquisition Company (Announced)
-.64% ~ $ 10.82 | NBST – Newbury Street Acquisition Corporation (Announced)

SPAC DEAL TERMINATIONS (Last 10 Days)
2024-08-26: NNAG + NAVA HEALTH MD, INC.

LATEST SPAC IPO PERFORMANCE
Aug 29 | $ 9.95 | GIG – GigCapital7 Corp.
Aug 28 | $ 9.95 | BSII – Black Spade Acquisition II Co
Aug 16 | $ 10.00 | HOND – HCM II Acquisition Corp.
Aug 16 | $ 10.02 | SBXD – SilverBox Corp IV
Aug 09 | $ 9.98 | VACH – Voyager Acquisition Corp
Aug 06 | $ 9.95 | EQV – EQV Ventures Acquisition Corp.

Recent Analysis

2026 Proxy Season Scorecard: Six Say-on-Pay Failures, AI Lands on Mega-Cap Ballots, and the Anti-ESG Pile-Up

Through May 21, 2026, U.S. public-company shareholders rejected six annual-meeting Say-on-Pay packages outright, voted against 18 directors at 14 companies, and crushed dozens of mega-cap shareholder proposals at sub-3% support. Plus: AI proposals filed at Alphabet, Meta, Walmart, and IBM; the split verdict on special-meeting rights; the activist-vote scorecard from four 2026 director-slate contests.

Weekly Recap: MO, OHI, WEN Rewire the C-Suite — May 22, 2026

Succession moved from emergency cleanup to portfolio rotation this week, with 24 CEO changes and 21 CFO changes across the tracked C-suite. Altria paired a CEO handoff with a CFO change, Omega Healthcare reset three senior finance and operating seats, and Wendy’s went back to the CEO market for the third time in three years.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.